Multiple Sclerosis Banner

Featured Article

Ask the Expert: Managing Urinary Retention in Multiple Sclerosis

Ask the Expert: Managing Urinary Retention in Multiple Sclerosis

John Stoffel, MD, Professor of Urology, Service Chief, and Associate Chair for Ambulatory Urology in the University of Michigan Department of Urology discusses the management of urinary retention in patients with MS.

Latest

Visualizing Peripheral Nerve Involvement in MS With Magnetic Resonance Neurography

Visualizing Peripheral Nerve Involvement in MS With Magnetic Resonance Neurography

Peripheral nerve involvement can be visualized and quantified by high-resolution MRN in MS patients.

Risk of Multiple Sclerosis Associated With Epstein-Barr, Cytomegalovirus Infection

Risk of Multiple Sclerosis Associated With Epstein-Barr, Cytomegalovirus Infection

Investigators strived to determine the association between multiple sclerosis and Epstein-Barr virus or cytomegalovirus infection in blacks and Hispanics.

Drug May Slow Conversion to Definite MS From Clinically Isolated Syndrome

Drug May Slow Conversion to Definite MS From Clinically Isolated Syndrome

Aubagio may cause delays in conversion to clinical definite MS by slowing the loss of cortical grey matter.

Switch to Alemtuzumab Reduces MS Disease Activity

Switch to Alemtuzumab Reduces MS Disease Activity

Patients experienced reduced disease activity when switched to alemtuzumab.

Dimethyl Fumarate as Exit Strategy From Natalizumab Treatment in Multiple Sclerosis

Dimethyl Fumarate as Exit Strategy From Natalizumab Treatment in Multiple Sclerosis

Patients with relapsing-remittingmultiple sclerosis with high titers of JCV antibodies and who were being treated with natalizumab for more than 2 years were enrolled in the study.

Disability Progression Slowed in Relapsing MS With Ocrelizumab Treatment

Disability Progression Slowed in Relapsing MS With Ocrelizumab Treatment

Data show superiority of OCREVUS compared to Rebif in reducing disability progression independent of relapse activity in people with RMS.

Novel Multiple Sclerosis Drug Shows Promise

Novel Multiple Sclerosis Drug Shows Promise

Celgene announced new Phase 3 data evaluating the safety and efficacy of ozanimod vs Avonex for RMS.

Fingolimod Promising for Pediatric Relapsing Multiple Sclerosis

Fingolimod Promising for Pediatric Relapsing Multiple Sclerosis

There are no FDA-approved MS therapies for the pediatric population.

Comorbidities in Multiple Sclerosis Associated With Diagnostic Delays, Mortality Risk

Comorbidities in Multiple Sclerosis Associated With Diagnostic Delays, Mortality Risk

As early treatment of multiple sclerosis is crucial, it is important to identify the factors that may delay diagnosis.

Comorbidities May Increase Relapse Risk in Multiple Sclerosis

Comorbidities May Increase Relapse Risk in Multiple Sclerosis

An emerging line of inquiry suggests a potential association between comorbidities and MS relapses, but studies have been limited.

Sign Up for Free e-newsletters

CME Focus